Editorial Feature

Could Sensors Help Detect Alzheimer's Disease?

Alzheimer's disease (AD) is a serious neurodegenerative condition and the major cause of dementia. The current diagnostic methods are time-consuming, expensive, and intrusive and do not represent a standardized approach for the early detection of AD. This article focuses on how sensor technology can aid in the early detection of Alzheimer's disease.

Image Credit: Atthapon Raksthaput/Shutterstock.com

Alzheimer’s Disease and its Epidemiology

Alzheimer’s disease is defined by the build-up of fibrillar amyloid β (Aβ) peptides and hyperphosphorylated tau protein aggregates in extracellular plaques and intracellular neurofibrillary tangles respectively. Typically, these pathological alterations take place years before the patient experiences any clinical symptoms.

Mild cognitive impairment (MCI) is the initial stage of AD. It is characterized by obscured memory episodes and impairments that are not memory related.

It progresses to dementia symptoms, including weakening cognitive processes, memory loss, difficulty performing daily tasks, and space and time disorientation.

The World health organization (WHO) and Alzheimer's disease international statistics suggest this incurable disease has already affected approximately 50 million people. By the year 2050, the figure is expected to rise to 152 million. Although it primarily affects elderly individuals, in 4% of cases, it also manifests before the age of 65, making it a multifaceted disease.

Current Detection Tools and its Limitations

Preclinical AD diagnosis is essential since treatment cannot block or reverse the disease's course once clinical symptoms appear. Recent findings indicate that early diagnosis can minimize the likelihood of developing AD by one-third.

The conventional detection techniques include imaging methods and cognitive tests. Mainly positron emission tomography (PET), near-infrared (NIR), and magnetic resonance imaging (MRI) are employed to find anomalies in patient’s brain.

Enzyme-linked immunosorbent assays (ELISA) and immunohistochemistry have also been adopted to measure cerebrospinal fluid and blood plasma biomarkers.

However, their practical applications are constrained by the radiation exposure of PET imaging, high cost, as well as the challenging and time-consuming nature of poor sensitivity immunosorbent tests. Hence, the fabrication of rapid and simple detection technologies is the need of the hour. 

Sensor Technology for the Detection of Alzheimer’s Disease

Sensor technologies overcome these limitations and have led to simple, affordable, sensitive sensing-based methods for AD early detection. Sensors require less amount of the sample, which would help to minimize the extraction procedures conducted on patients.

Sensors can quickly recognize and detect biomarkers that indicate the onset of AD. A unique label-free biosensor designed with MoS2 diodes has been recently built by the Simon Fraser University (SFU) Nanodevice Fabrication Group. It can be employed to detect diseases like Alzheimer's.

An aberrant fluctuation in cytokine levels is a sign of uncontrolled inflammatory responses that have been associated with Alzheimer's disease. Tumor necrosis factor (TNF), a pro-inflammatory cytokine, can be detected by this MoS2 diode-based sensor, according to the results that were published in the journal Nature Communications.

TNF-binding aptamers have been added to the sensor device to enable the detection of TNF- at levels ~ 10 fM, which is far lower than the levels detected in healthy blood.

The fundamental biomarkers of Alzheimer's disease, including total tau protein (t-tau), beta-amyloid42 (Aβ42), beta-amyloid40 (Aβ40), and phosphorylated tau protein (p-tau181), have been measured by another study team at the ‘Korea Advanced Institute of Science and Technology’ (KAIST).

The clinically tested and accurate multi-plexed electrical biosensor is built on carbon nanotubes (CNT) with a low manufacturing cost that was produced using the Langmuir-Blodgett process.

The biosensor was able to concurrently detect the levels of Alzheimer's disease biomarkers with an overall 90% sensitivity and selectivity and 88.6% accuracy rate.

Alzheimer’s disease has a 15 to 20-year asymptomatic phase before the initial clinical symptoms manifest. Researchers have found that Alzheimer's disease can be detected in the bloodstream up to seventeen years before any observable symptoms appear.

Misfolding, which causes characteristic plaque-like deposits in the brain, marks the disease's progression. In a recent article published in the journal ‘Alzheimer's & Dementia: The Journal of the Alzheimer's Association’ these researchers described the data curated from their use of the immuno-infrared sensor. 

The sensor detects the amount of the glial fiber protein (a hallmark of astrogliosis) and the protein biomarker amyloid-beta, which is responsible for the misfolding.

Fluorescence sensors have recently achieved wide use as a potent tool for screening biomarkers in-vitro / in-vivo. This is because of their high signal alterations when exposed to certain analytes.

Yi and colleagues developed a water-soluble, quinoline-malononitrile-based near-infrared (NIR) sensor with intramolecular charge transfer that showed fluorescence "turn-on" after specifically attaching to Aβ aggregates.

Wearable biosensors are also utilized to detect lower limb mobility in AD patients for early disease diagnosis. 

A wearable internet-of-things device was developed by Varatharajan et al. to detect Alzheimer's disease. Real-time tracking of the leg movements of AD patients is done using a force sensor-based device. Despite simply measuring foot mobility in this study, it has been shown to be a reliable method for detecting Alzheimer's disease.

The wearable biosensor technology has various benefits, including portability, comfort, and simplicity, enabling ongoing point-of-care (POC) testing.

Still, these developments come with a few disadvantages, such as the fact that some of these devices are uncomfortable to wear, disorientating, and stressful. Hence, non-wearable biosensors (as previously described) are introduced with minimal disruption to individuals.

Future Outlook

Early diagnosis of AD is essential to postpone the onset of degenerative symptoms to the maximum extent possible and to give family members and caretakers enough time to adjust to the related changes.

Thus, the development of a novel diagnostic tool for the identification of early AD biomarkers is necessary. Although blood serum and CSF are complex samples that may interfere with the measured values, achieving adequate sensitivity and selectivity is the key challenge to be solved in this situation.

Sensor technologies can quickly identify Alzheimer's disease and offer good sensitivity and selectivity.

The transferability of the developed biosensors is hampered by the fact that long-term stability and efficiency are often neglected in many investigations, despite the fact that sensitivity and selectivity problems appearing to be resolved once fM and pM limits of detection are achieved.

Consequently, clinical trials can be conducted in the future to validate the long-term efficacy of sensors with the goal of making them commercially available.

Continue reading: Portable Sensors are Bringing in a New Era of Medical Technologies

References and Further Reading

Beyer, L., Stocker, H., Rujescu, D., Holleczek, B., Stockmann, J., Nabers, A., Brenner, H., & Gerwert, K. (2022). Amyloid-beta misfolding and GFAP predict risk of clinical Alzheimer’s disease diagnosis within 17 years. Alzheimer’s & Dementia. doi.org/10.1002/ALZ.12745

De Silva, T., Fawzy, M., Hasani, A., Ghanbari, H., Abnavi, A., Askar, A., Ling, Y., Mohammadzadeh, M. R., Kabir, F., Ahmadi, R., Rosin, M., Kavanagh, K. L., & Adachi, M. M. (2022). Ultrasensitive rapid cytokine sensors based on asymmetric geometry two-dimensional MoS2 diodes. Nature Communications, 13(1), pp. 1–10. https://doi.org/10.1038/s41467-022-35278-2

Early Alzheimer’s disease detection sensor in development. (n.d.). Availablt at:  https://www.openaccessgovernment.org/early-alzheimers-disease-detection-sensor-brain/151644/.

Li, F., Stewart, C., Yang, S., Shi, F., Cui, W., Zhang, S., Wang, H., Huang, H., Chen, M., & Han, J. (2017). Optical Sensor Array for the Early Diagnosis of Alzheimer’s Disease. doi.org/10.3389/fchem.2022.874864

Toyos-Rodríguez, C., García-Alonso, F. J., & de la Escosura-Muñiz, A. (2020). Electrochemical Biosensors Based on Nanomaterials for Early Detection of Alzheimer’s Disease. Sensors, 20(17), p. 4748. https://doi.org/10.3390/S20174748

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.

Arzoo Puri

Written by

Arzoo Puri

Ms. Arzoo Puri has a Master’s degree in biomedical sciences and believes that science is constantly advancing thereby creating new discoveries each day.  She likes to utilize her skills and experience to contribute to the astounding medical advancements that take place every day. In 2022, she completed her master's dissertation and research training from Nanobios Lab, IIT-Bombay, India, and has finished her position as a scientific writer at Eureka, which she had undertaken while pursuing her masters. Her core interests lie in nanotechnology-based research, biomedical science and cannabis science. Her research goals are mainly directed toward the field of biosensors, point-of-care testing devices, bioimplants, drug delivery, medical diseases, and nanomaterials such as Graphene quantum dots.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Puri, Arzoo. (2023, March 09). Could Sensors Help Detect Alzheimer's Disease?. AZoSensors. Retrieved on June 20, 2024 from https://www.azosensors.com/article.aspx?ArticleID=2763.

  • MLA

    Puri, Arzoo. "Could Sensors Help Detect Alzheimer's Disease?". AZoSensors. 20 June 2024. <https://www.azosensors.com/article.aspx?ArticleID=2763>.

  • Chicago

    Puri, Arzoo. "Could Sensors Help Detect Alzheimer's Disease?". AZoSensors. https://www.azosensors.com/article.aspx?ArticleID=2763. (accessed June 20, 2024).

  • Harvard

    Puri, Arzoo. 2023. Could Sensors Help Detect Alzheimer's Disease?. AZoSensors, viewed 20 June 2024, https://www.azosensors.com/article.aspx?ArticleID=2763.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this article?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.